{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.54","value":"4.2"},{"groupId":"OG001","spread":"2.09","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 0.5 hr post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.47","value":"5.4"},{"groupId":"OG001","spread":"2.00","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 1 hr post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.56","value":"5.5"},{"groupId":"OG001","spread":"2.12","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 2 hr post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.43","value":"1.8"},{"groupId":"OG001","spread":"3.28","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 4 hr post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.37","value":"1.7"},{"groupId":"OG001","spread":"3.12","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 6 hr post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.53","value":"2.3"},{"groupId":"OG001","spread":"3.36","value":"-3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Change at 8 hr post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Baseline was defined as the mean of the measured ECG intervals collected at 3 time points (-1 hour, -0.5 hour, and 0 hour) prior to treatment administration on Cycle 1 Day 1 (Cycle length= 28 days)","dispersionType":"Standard Error","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG000","title":"QTc Substudy: Imetelstat Sodium"},{"description":"Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. If after a minimum of 2 treatment cycles a participant has no significant change to pRBC transfusion burden or evidence of clinical benefit per Investigator, after discussion with the Sponsor the participant, he/she may be permitted to start treatment with imetelstat sodium.","id":"OG001","title":"QTc Substudy: Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The QTc substudy analysis set included all participants who participated in QTc substudy and received at least one dose of study drug, with measurements at baseline as well as on-treatment with at least 1 post-dose time point with a ΔQTcF value. By-time Point Analysis Set included each post-baseline time point that had a non-missing change-from-baseline observation. Number analysed is the number of participants with data available for analysis at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1, Day 1: 0.5, 1, 2, 4, 6, and 8 hours post-dose (cycle length= 28 days)","title":"QTc Substudy: Change From Baseline in QT Interval by Fridericia's Correction Method (ΔQTcF)","type":"SECONDARY","unitOfMeasure":"milliseconds (ms)"}